Other Information
−Removed: No ne of our officers or directors, as defined in Rule 16a-1(f), adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K, during the three months ended June 30, 2025.
+Added: No ne of our officers or directors, as defined in Rule 16a-1(f), adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K, during the three months ended September 30, 2025.
The following exhibits are incorporated by reference or filed or furnished as part of this report.
Incorporated by Reference Herein
−Removed: Form of Amendment No.
−Removed: 1 to the Amended and Restated Depositary Agreement, by and among Amarin Corporation plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder
−Removed: Registration Statement on Form F-6 POS, as Exhibit (a)(i)
−Removed: March 12, 2025
−Removed: License and Supply Agreement, dated June 20, 2025, by and between Amarin Pharmaceuticals Ireland Limited and Recordati Industria Chimica e Farmaceutica S.p.A.**
+Added: Form of Second Amended and Restated Deposit Agreement among Amarin Corporation plc, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder, including the Form of ADR attached as Exhibit A thereto
+Added: Registration Statement on Form F-6, Exhibit (a)
+Added: July 23, 2025
+Added: Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated February 25, 2022*
Current Report on Form 8-K as Exhibit 10.1
−Removed: June 24, 2025
−Removed: Amended and Restated Non-Employee Director Compensation Policy
−Removed: Filed herewith
−Removed: Form of Deed of Indemnity
−Removed: Filed herewith
+Added: October 22, 2025
+Added: First Amendment to the Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated July 17, 2023*
+Added: Current Report on Form 8-K as Exhibit 10.2
+Added: October 22, 2025
+Added: Second Amendment to the Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated October 6, 2025*
+Added: Current Report on Form 8-K as Exhibit 10.3
+Added: October 22, 2025
Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002
17 unchanged sentences
Filed herewith
−Removed: ** Portions omitted pursuant to Item 601(b)(10) of Regulation S-K.
−Removed: The Company will supplementally furnish an unredacted copy of the exhibit upon request by Securities and Exchange Commission.
−Removed: Management contract, compensatory plan or arrangement.
+Added: * Management contract or compensatory plan or arrangement.
+Added: Certain personal information in this exhibit has been omitted in accordance with Regulation S-K Item 601(a)(6).
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
4 unchanged sentences
(On behalf of the Registrant)
−Removed: July 30, 2025
+Added: October 29, 2025
AMARIN CORPORATION PLC
4 unchanged sentences
(On behalf of the Registrant)
−Removed: July 30, 2025
+Added: October 29, 2025
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.